Assenagon Asset Management
SNDX icon

Assenagon Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Assenagon Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$912K Hold
41,737
– – ﹤0.01% 984
2026
Q1 		$975K Hold
41,737
– – ﹤0.01% 900
2025
Q4 		$877K Sell
41,737
-1,742,402
-98% -$30.4M ﹤0.01% 960
2025
Q3 		$27.4M Sell
1,784,139
-255,848
-13% -$3.35M 0.04% 319
2025
Q2 		$19.1M Hold
2,039,987
– – 0.03% 361
2025
Q1 		$25.1M Sell
2,039,987
-24,469
-1% -$345K 0.04% 296
2024
Q4 		$27.3M Buy
2,064,456
+1,598,428
+343% +$27.4M 0.04% 306
2024
Q3 		$8.97M Buy
466,028
+37,079
+9% +$766K 0.02% 562
2024
Q2 		$8.81M Buy
428,949
+151,021
+54% +$3.16M 0.02% 467
2024
Q1 		$6.61M Sell
277,928
-134,037
-33% -$2.99M 0.02% 529
2023
Q4 		$8.9M Buy
411,965
+21,427
+5% +$329K 0.02% 482
2023
Q3 		$5.67M Buy
390,538
+125,893
+48% +$2.38M 0.02% 550
2023
Q2 		$5.54M Sell
264,645
-74,947
-22% -$1.56M 0.02% 477
2023
Q1 		$7.17M Buy
339,592
+329,577
+3,291% +$8.2M 0.03% 469
2022
Q4 		$255K Sell
10,015
-10,106
-50% -$236K ﹤0.01% 1280
2022
Q3 		$484K Sell
20,121
-190,623
-90% -$4.28M ﹤0.01% 1105
2022
Q2 		$4.05M Buy
+210,744
New +$3.51M 0.02% 609
2022
Q1 		– Sell
-283,954
Closed -$6.22M – 1551
2021
Q4 		$6.22M Buy
+283,954
New +$5.25M 0.02% 457
2020
Q4 		– Sell
-169,792
Closed -$2.51M – 1241
2020
Q3 		$2.51M Sell
169,792
-8,400
-5% -$128K 0.01% 539
2020
Q2 		$2.64M Buy
+178,192
New +$2.71M 0.02% 511

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Assenagon Asset Management's SNDX Position: Q2 2026 in Review

Assenagon Asset Management held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 41,737 shares worth $912K. The position accounts for ﹤0.01% of the portfolio, ranked #984.

Assenagon Asset Management first reported a position in SNDX in Q2 2020 and has held it in 20 quarters since. The position peaked at $27.4M in Q3 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Assenagon Asset Management held 41,737 shares of Syndax Pharmaceuticals worth $912K as of Q2 2026.
  • Assenagon Asset Management left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #984 holding.
  • Assenagon Asset Management first reported a position in Syndax Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
  • Assenagon Asset Management's Syndax Pharmaceuticals position peaked at $27.4M in Q3 2025.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.